<DOC>
	<DOCNO>NCT01767363</DOCNO>
	<brief_summary>This retrospective cohort study ass association benign prostatic hyperplasia ( BPH ) treatment ( 5-alpha reductase inhibitor ( 5ARI ) alpha-blocker medication ) occurrence prostate cancer relate mortality . This study also assess number secondary endpoint include prostate cancer mortality metastatic prostate cancer , cause mortality .</brief_summary>
	<brief_title>WEUSKOP5723 : Prostate Cancer Study</brief_title>
	<detailed_description>A retrospective cohort study 1992-2010 conduct use data 4 Kaiser site : Kaiser Permanente Southern California ( KPSC ) , Kaiser Permanente Northern California ( KPNC ) , Kaiser Permanente Northwest ( KPNW ) , Kaiser Permanente Colorado ( KPCO ) . Men treat BPH medication , 5ARIs ( without concomitant and/or previous alpha-blocker use ) compare men treat alpha-blocker . A matched design use man treat 5ARIs match 5 6 men treat alpha-blocker . Men 50 year old time first prescription study define BPH medication , initiate treatment 1992 2008 least 1-year coverage healthcare system first prescription BPH medication least 3 consecutive prescription ( 90 day supply ) BPH medication eligible inclusion study . Men diagnosis prostate cancer time first prescription BPH medication , diagnosis prostate cancer within 3 month initiation first BPH medication , treat finasteride 1mg prior BPH medication exclude study . 5ARI initiator match alpha-blocker user ratio 1:5 1:6 yield overall match ratio 1:5.4 . Matching factor include age ( +/- 1 year ) , time BPH treatment initiation ( +/- 1 year ) , race , duration prior use alpha-blocker . Based feasibility study KPSC , approximately 284,000 men treat BPH medication meet eligibility criterion inclusion study sample . The data analyze use Kaplan Meier curve compare 5ARI vs alpha-blocker user primary secondary study outcome , without adjustment . Additionally , plot cumulative incidence , adjust compete risk death , construct allow investigation effect compete risk Kaplan-Meier probability estimate . Crude mortality rate incidence rate metastatic cancer calculate . Cox proportional hazard regression model fit compare primary secondary outcome group use hazard ratio , adjust pre-treatment characteristic .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Hyperplasia</mesh_term>
	<mesh_term>Prostatic Hyperplasia</mesh_term>
	<mesh_term>5-alpha Reductase Inhibitors</mesh_term>
	<mesh_term>Adrenergic alpha-Antagonists</mesh_term>
	<criteria>Patients Male Patients new prescription BPH medication ( 5ARI and/or alphablocker ) 1992 later identify appropriate treatment BPH/LUTS KP National Pharmacy guideline . Patients treatment BPH medication must initiate prior Jan1 , 2008 . Patients age 50 year old time treatment 5ARI alphablocker . Patients least 1year coverage healthcare system first prescription BPH medication ( 5ARI and/or alphablocker ) . Patients least 3 consecutive prescription ( 90 day supply ) BPH medication ( 5ARI and/or alphablocker ) . Patients diagnosis prostate cancer time first prescription BPH medication ( 5ARI and/or alphablocker ) . Patients dagnosis prostate cancer within 3 month first BPH medication ( 5ARI and/or alphablocker ) Patients treat Finasteride 1mg prior BPH medication . Finasteride 1mg dose approve androgenic alopecia target population study men treat BPH , exclude men treat 1mg dose .</criteria>
	<gender>Male</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>5-alpha reductase inhibitor</keyword>
	<keyword>benign prostatic hyperplasia treatment</keyword>
	<keyword>Prostate cancer mortality</keyword>
</DOC>